Top

Published in:

01-05-2017 | Review

The Central Nervous System and Bone Metabolism: An Evolving Story

Authors: Paul Dimitri, Cliff Rosen

Published in: Calcified Tissue International | Issue 5/2017

Abstract

Our understanding of the control of skeletal metabolism has undergone a dynamic shift in the last two decades, primarily driven by our understanding of energy metabolism. Evidence demonstrating that leptin not only influences bone cells directly, but that it also plays a pivotal role in controlling bone mass centrally, opened up an investigative process that has changed the way in which skeletal metabolism is now perceived. Other central regulators of bone metabolism have since been identified including neuropeptide Y (NPY), serotonin, endocannabinoids, cocaine- and amphetamine-regulated transcript (CART), adiponectin, melatonin and neuromedin U, controlling osteoblast and osteoclast differentiation, proliferation and function. The sympathetic nervous system was originally identified as the predominant efferent pathway mediating central signalling to control skeleton metabolism, in part regulated through circadian genes. More recent evidence points to a role of the parasympathetic nervous system in the control of skeletal metabolism either through muscarinic influence of sympathetic nerves in the brain or directly via nicotinic receptors on osteoclasts, thus providing evidence for broader autonomic skeletal regulation. Sensory innervation of bone has also received focus again widening our understanding of the complex neuronal regulation of bone mass. Whilst scientific advance in this field of bone metabolism has been rapid, progress is still required to understand how these model systems work in relation to the multiple confounders influencing skeletal metabolism, and the relative balance in these neuronal systems required for skeletal growth and development in childhood and maintaining skeletal integrity in adulthood.

Zhang Y et al (1994) Positional cloning of the mouse obese gene and its human homologue. Nature 372(6505):425–432PubMedCrossRef

Halaas JL et al (1995) Weight-reducing effects of the plasma protein encoded by the obese gene. Science 269(5223):543–546PubMedCrossRef

Friedman J (2014) 20 years of leptin: leptin at 20: an overview. J Endocrinol 223(1):T1–T8PubMedCrossRef

Thomas T et al (1999) Leptin acts on human marrow stromal cells to enhance differentiation to osteoblasts and to inhibit differentiation to adipocytes. Endocrinology 140(4):1630–1638PubMed

Cornish J et al (2002) Leptin directly regulates bone cell function in vitro and reduces bone fragility in vivo. J Endocrinol 175(2):405–415PubMedCrossRef

Gordeladze JO et al (2002) Leptin stimulates human osteoblastic cell proliferation, de novo collagen synthesis, and mineralization: impact on differentiation markers, apoptosis, and osteoclastic signaling. J Cell Biochem 85(4):825–836PubMedCrossRef

Holloway WR et al (2002) Leptin inhibits osteoclast generation. J Bone Miner Res 17(2):200–209PubMedCrossRef

Ducy P et al (2000) Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 100(2):197–207PubMedCrossRef

Tartaglia LA et al (1995) Identification and expression cloning of a leptin receptor. OB-R. Cell 83(7):1263–1271PubMedCrossRef

10.

Takeda S et al (2002) Leptin regulates bone formation via the sympathetic nervous system. Cell 111(3):305–317PubMedCrossRef

11.

Walther DJ et al (2003) Synthesis of serotonin by a second tryptophan hydroxylase isoform. Science 299(5603):76PubMedCrossRef

12.

Schmitt JA et al (2006) Serotonin and human cognitive performance. Curr Pharm Des 12(20):2473–2486PubMedCrossRef

13.

Alenina N, Klempin F (2015) The role of serotonin in adult hippocampal neurogenesis. Behav Brain Res 277:49–57PubMedCrossRef

14.

Kode A et al (2014) Lrp5 regulation of bone mass and serotonin synthesis in the gut. Nat Med 20(11):1228–1229PubMedCrossRef

15.

Yadav VK et al (2008) Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell 135(5):825–837PubMedPubMedCentralCrossRef

16.

Gong Y et al (2001) LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 107(4):513–523PubMedCrossRef

17.

Feuer AJ et al (2015) Use of selective serotonin reuptake inhibitors and bone mass in adolescents: an NHANES study. Bone 78:28–33PubMedCrossRef

18.

Sheu YH et al (2015) SSRI use and risk of fractures among perimenopausal women without mental disorders. Inj Prev 21(6):397–403PubMedCrossRef

19.

Rauma PH et al (2016) Effects of antidepressants on postmenopausal bone loss—A 5 year longitudinal study from the OSTPRE cohort. Bone 89:25–31PubMedCrossRef

20.

Cui Y et al (2011) Lrp5 functions in bone to regulate bone mass. Nat Med 17(6):684–691PubMedPubMedCentralCrossRef

21.

Cui Y et al (2014) Reply to Lrp5 regulation of bone mass and gut serotonin synthesis. Nat Med 20(11):1229–1230PubMedCrossRef

22.

Kode A et al (2014) Lrp5 regulation of bone mass and serotonin synthesis in the gut. Nat Med 20(11):1228–1229PubMedCrossRef

23.

Yadav VK et al (2009) A serotonin-dependent mechanism explains the leptin regulation of bone mass, appetite, and energy expenditure. Cell 138(5):976–989PubMedPubMedCentralCrossRef

24.

Oury F et al (2010) CREB mediates brain serotonin regulation of bone mass through its expression in ventromedial hypothalamic neurons. Genes Dev 24(20):2330–2342PubMedPubMedCentralCrossRef

25.

Yadav VK et al (2011) Leptin-dependent serotonin control of appetite: temporal specificity, transcriptional regulation, and therapeutic implications. J Exp Med 208(1):41–52PubMedPubMedCentralCrossRef

26.

Sandhu HS, Herskovits MS, Singh IJ (1987) Effect of surgical sympathectomy on bone remodeling at rat incisor and molar root sockets. Anat Rec 219(1):32–38PubMedCrossRef

27.

Schwartzman RJ (2000) New treatments for reflex sympathetic dystrophy. N Engl J Med 343(9):654–656PubMedCrossRef

28.

Mano T, Nishimura N, Iwase S (2010) Sympathetic neural influence on bone metabolism in microgravity. Acta Physiol Hung 97(4):354–361PubMedCrossRef

29.

Vignaux G et al (2015) Inner ear vestibular signals regulate bone remodeling via the sympathetic nervous system. J Bone Miner Res 30(6):1103–1111PubMedPubMedCentralCrossRef

30.

Vignaux G et al (2013) Bone remodeling is regulated by inner ear vestibular signals. J Bone Miner Res 28(10):2136–2144PubMedCrossRef

31.

Elefteriou F et al (2005) Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature 434(7032):514–520PubMedCrossRef

32.

Kondo H, Togari A (2011) Continuous treatment with a low-dose beta-agonist reduces bone mass by increasing bone resorption without suppressing bone formation. Calcif Tissue Int 88(1):23–32PubMedCrossRef

33.

Motyl KJ et al (2015) Propranolol attenuates risperidone-induced trabecular bone loss in female mice. Endocrinology 156(7):2374–2383PubMedPubMedCentralCrossRef

34.

Blomqvist AG, Herzog H (1997) Y-receptor subtypes–how many more? Trends Neurosci 20(7):294–298PubMedCrossRef

35.

Stanley BG et al (1986) Neuropeptide Y chronically injected into the hypothalamus: a powerful neurochemical inducer of hyperphagia and obesity. Peptides 7(6):1189–1192PubMedCrossRef

36.

Erickson JC, Hollopeter G, Palmiter RD (1996) Attenuation of the obesity syndrome of ob/ob mice by the loss of neuropeptide Y. Science 274(5293):1704–1707PubMedCrossRef

37.

Baldock PA et al (2005) Hypothalamic control of bone formation: distinct actions of leptin and Y2 receptor pathways. J Bone Miner Res 20(10):1851–1857PubMedCrossRef

38.

Baldock PA et al (2009) Neuropeptide Y knockout mice reveal a central role of NPY in the coordination of bone mass to body weight. PLoS One 4(12):e8415PubMedPubMedCentralCrossRef

39.

Baldock PA et al (2006) Hypothalamic regulation of cortical bone mass: opposing activity of Y2 receptor and leptin pathways. J Bone Miner Res 21(10):1600–1607PubMedCrossRef

40.

Sainsbury A et al (2003) Synergistic effects of Y2 and Y4 receptors on adiposity and bone mass revealed in double knockout mice. Mol Cell Biol 23(15):5225–5233PubMedPubMedCentralCrossRef

41.

Shi YC, Baldock PA (2012) Central and peripheral mechanisms of the NPY system in the regulation of bone and adipose tissue. Bone 50(2):430–436PubMedCrossRef

42.

Shao P, Ohtsuka-Isoya M, Shinoda H (2003) Circadian rhythms in serum bone markers and their relation to the effect of etidronate in rats. Chronobiol Int 20(2):325–336PubMedCrossRef

43.

Buijs FN et al (2016) The circadian system: a regulatory feedback network of periphery and brain. Physiology (Bethesda) 31(3):170–181

44.

Reppert SM, Weaver DR (2002) Coordination of circadian timing in mammals. Nature 418(6901):935–941PubMedCrossRef

45.

Schibler U, Sassone-Corsi P (2002) A web of circadian pacemakers. Cell 111(7):919–922PubMedCrossRef

46.

Fu L et al (2005) The molecular clock mediates leptin-regulated bone formation. Cell 122(5):803–815PubMedCrossRef

47.

McElderry JD et al (2013) Tracking circadian rhythms of bone mineral deposition in murine calvarial organ cultures. J Bone Miner Res 28(8):1846–1854PubMedPubMedCentralCrossRef

48.

Xu C et al (2016) Circadian clock regulates bone resorption in mice. J Bone Miner Res 31(7):1344–1355PubMedCrossRef

49.

Boucher H et al (2016) Circadian clock genes modulate human bone marrow mesenchymal stem cell differentiation, migration and cell cycle. PLoS One 11(1):e0146674PubMedPubMedCentralCrossRef

50.

Kuhar MJ et al (2002) CART peptides. Neuropeptides 36(1):1–8PubMedCrossRef

51.

Vicentic A (2006) CART peptide diurnal variations in blood and brain. Peptides 27(8):1942–1948PubMedCrossRef

52.

Wierup N, Sundler F (2006) CART is a novel islet regulatory peptide. Peptides 27(8):2031–2036PubMedCrossRef

53.

Kristensen P et al (1998) Hypothalamic CART is a new anorectic peptide regulated by leptin. Nature 393(6680):72–76PubMedCrossRef

54.

Ahn JD et al (2006) Cart overexpression is the only identifiable cause of high bone mass in melanocortin 4 receptor deficiency. Endocrinology 147(7):3196–3202PubMedCrossRef

55.

Singh MK, Elefteriou F, Karsenty G (2008) Cocaine and amphetamine-regulated transcript may regulate bone remodeling as a circulating molecule. Endocrinology 149(8):3933–3941PubMedPubMedCentralCrossRef

56.

Tien D et al (2003) Vagal afferents are necessary for the establishment but not the maintenance of kainic acid-induced hyperalgesia in mice. Pain 102(1–2):39–49PubMedCrossRef

57.

Shi Y et al (2010) Signaling through the M(3) muscarinic receptor favors bone mass accrual by decreasing sympathetic activity. Cell Metab 11(3):231–238PubMedPubMedCentralCrossRef

58.

Bajayo A et al (2012) Skeletal parasympathetic innervation communicates central IL-1 signals regulating bone mass accrual. Proc Natl Acad Sci USA 109(38):15455–15460PubMedPubMedCentralCrossRef

59.

Eimar H et al (2013) Cholinergic regulation of bone. J Musculoskelet Neuronal Interact 13(2):124–132PubMed

60.

Offley SC et al (2005) Capsaicin-sensitive sensory neurons contribute to the maintenance of trabecular bone integrity. J Bone Miner Res 20(2):257–267PubMedCrossRef

61.

Ding Y et al (2010) Effects of capsaicin-induced sensory denervation on bone metabolism in adult rats. Bone 46(6):1591–1596PubMedCrossRef

62.

Cornish J et al (2001) Effects of calcitonin, amylin, and calcitonin gene-related peptide on osteoclast development. Bone 29(2):162–168PubMedCrossRef

63.

Ishizuka K et al (2005) Inhibitory effect of CGRP on osteoclast formation by mouse bone marrow cells treated with isoproterenol. Neurosci Lett 379(1):47–51PubMedCrossRef

64.

Wang L et al (2010) Calcitonin-gene-related peptide stimulates stromal cell osteogenic differentiation and inhibits RANKL induced NF-kappaB activation, osteoclastogenesis and bone resorption. Bone 46(5):1369–1379PubMedCrossRef

65.

Okajima K et al (2004) Activation of capsaicin-sensitive sensory neurons by carvedilol, a nonselective beta-blocker, in spontaneous hypertensive rats. J Pharmacol Exp Ther 309(2):684–691PubMedCrossRef

66.

Cherruau M et al (2003) Chemical sympathectomy-induced changes in TH-, VIP-, and CGRP-immunoreactive fibers in the rat mandible periosteum: influence on bone resorption. J Cell Physiol 194(3):341–348PubMedCrossRef

67.

Brighton PJ, Szekeres PG, Willars GB (2004) Neuromedin U and its receptors: structure, function, and physiological roles. Pharmacol Rev 56(2):231–248PubMedCrossRef

68.

Vigo E et al (2007) Novel role of the anorexigenic peptide neuromedin U in the control of LH secretion and its regulation by gonadal hormones and photoperiod. Am J Physiol Endocrinol Metab 293(5):E1265–E1273PubMedCrossRef

69.

Sato S et al (2007) Central control of bone remodeling by neuromedin U. Nat Med 13(10):1234–1240PubMedCrossRef

70.

Redman J, Armstrong S, Ng KT (1983) Free-running activity rhythms in the rat: entrainment by melatonin. Science 219(4588):1089–1091PubMedCrossRef

71.

Grossman E, Laudon M, Zisapel N (2011) Effect of melatonin on nocturnal blood pressure: meta-analysis of randomized controlled trials. Vasc Health Risk Manag 7:577–584PubMedPubMedCentral

72.

Cagnacci A, Elliott JA, Yen SS (1992) Melatonin: a major regulator of the circadian rhythm of core temperature in humans. J Clin Endocrinol Metab 75(2):447–452PubMed

73.

Slominski RM et al (2012) Melatonin membrane receptors in peripheral tissues: distribution and functions. Mol Cell Endocrinol 351(2):152–166PubMedPubMedCentralCrossRef

74.

Radio NM, Doctor JS, Witt-Enderby PA (2006) Melatonin enhances alkaline phosphatase activity in differentiating human adult mesenchymal stem cells grown in osteogenic medium via MT2 melatonin receptors and the MEK/ERK (1/2) signaling cascade. J Pineal Res 40(4):332–342PubMedCrossRef

75.

Zhang L et al (2010) Melatonin inhibits adipogenesis and enhances osteogenesis of human mesenchymal stem cells by suppressing PPARgamma expression and enhancing Runx2 expression. J Pineal Res 49(4):364–372PubMedCrossRef

76.

Park KH et al (2011) Melatonin promotes osteoblastic differentiation through the BMP/ERK/Wnt signaling pathways. J Pineal Res 51(2):187–194PubMedCrossRef

77.

Ostrowska Z et al (2002) The relationship between the daily profile of chosen biochemical markers of bone metabolism and melatonin and other hormone secretion in rats under physiological conditions. Neuro Endocrinol Lett 23(5–6):417–425PubMed

78.

Koyama H et al (2002) Melatonin at pharmacologic doses increases bone mass by suppressing resorption through down-regulation of the RANKL-mediated osteoclast formation and activation. J Bone Miner Res 17(7):1219–1229PubMedCrossRef

79.

Uslu S et al (2007) Constructive effect of exogenous melatonin against osteoporosis after ovariectomy in rats. Anal Quant Cytol Histol 29(5):317–325PubMed

80.

Egermann M et al (2011) Pinealectomy affects bone mineral density and structure–an experimental study in sheep. BMC Musculoskelet Disord 12:271PubMedPubMedCentralCrossRef

81.

Witt-Enderby PA et al (2012) Effects on bone by the light/dark cycle and chronic treatment with melatonin and/or hormone replacement therapy in intact female mice. J Pineal Res 53(4):374–384PubMedCrossRef

82.

Ladizesky MG et al (2001) Effect of melatonin on bone metabolism in ovariectomized rats. Life Sci 70(5):557–565PubMedCrossRef

83.

Cardinali DP et al (2003) Melatonin effects on bone: experimental facts and clinical perspectives. J Pineal Res 34(2):81–87PubMedCrossRef

84.

Amstrup AK et al (2015) Melatonin improves bone mineral density at the femoral neck in postmenopausal women with osteopenia: a randomized controlled trial. J Pineal Res 59(2):221–229PubMedCrossRef

85.

Howlett AC (2002) The cannabinoid receptors. Prostaglandins Other Lipid Mediat 68–69:619–631PubMedCrossRef

86.

Pertwee RG, Ross RA (2002) Cannabinoid receptors and their ligands. Prostaglandins Leukot Essent Fatty Acids 66(2–3):101–121PubMedCrossRef

87.

Mackie K (2008) Signaling via CNS cannabinoid receptors. Mol Cell Endocrinol 286(1–2 Suppl 1):S60–S65PubMedPubMedCentralCrossRef

88.

Ishac EJ et al (1996) Inhibition of exocytotic noradrenaline release by presynaptic cannabinoid CB1 receptors on peripheral sympathetic nerves. Br J Pharmacol 118:2023–2028PubMedPubMedCentralCrossRef

89.

Idris AI et al (2005) Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors. Nat Med 11(7):774–779PubMedPubMedCentralCrossRef

90.

Idris AI et al (2009) Cannabinoid receptor type 1 protects against age-related osteoporosis by regulating osteoblast and adipocyte differentiation in marrow stromal cells. Cell Metab 10(2):139–147PubMedCrossRef

91.

Tam J et al (2006) Involvement of neuronal cannabinoid receptor CB1 in regulation of bone mass and bone remodeling. Mol Pharmacol 70(3):786–792PubMedCrossRef

92.

Tam J et al (2008) The cannabinoid CB1 receptor regulates bone formation by modulating adrenergic signaling. FASEB J. 22(1):285–294PubMedCrossRef

93.

Idris AI et al (2008) Regulation of bone mass, osteoclast function, and ovariectomy-induced bone loss by the type 2 cannabinoid receptor. Endocrinology 149(11):5619–5626PubMedCrossRef

94.

Whyte LS et al (2012) Cannabinoids and bone: endocannabinoids modulate human osteoclast function in vitro. Br J Pharmacol 165(8):2584–2597PubMedPubMedCentralCrossRef

95.

Ofek O et al (2006) Peripheral cannabinoid receptor, CB2, regulates bone mass. Proc Natl Acad Sci USA 103(3):696–701PubMedPubMedCentralCrossRef

96.

Ofek O et al (2011) CB2 cannabinoid receptor targets mitogenic Gi protein-cyclin D1 axis in osteoblasts. J Bone Miner Res 26(2):308–316PubMedCrossRef

97.

Sophocleous A et al (2011) The type 2 cannabinoid receptor regulates bone mass and ovariectomy-induced bone loss by affecting osteoblast differentiation and bone formation. Endocrinology 152(6):2141–2149PubMedCrossRef

98.

Idris AI, Ralston SH (2012) Role of cannabinoids in the regulation of bone remodeling. Front Endocrinol (Lausanne) 3:136

99.

Stefan N, Stumvoll M (2002) Adiponectin–its role in metabolism and beyond. Horm Metab Res 34(9):469–474PubMedCrossRef

100.

Wu Y et al (2014) Central adiponectin administration reveals new regulatory mechanisms of bone metabolism in mice. Am J Physiol Endocrinol Metab 306(12):E1418–E1430PubMedPubMedCentralCrossRef

101.

Kajimura D et al (2013) Adiponectin regulates bone mass via opposite central and peripheral mechanisms through FoxO1. Cell 17(6):901–915

Title: The Central Nervous System and Bone Metabolism: An Evolving Story
Authors: Paul Dimitri
Cliff Rosen
Publication date: 01-05-2017
Publisher: Springer US
Published in: Calcified Tissue International / Issue 5/2017
Print ISSN: 0171-967X
Electronic ISSN: 1432-0827
DOI: https://doi.org/10.1007/s00223-016-0179-6

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

The Central Nervous System and Bone Metabolism: An Evolving Story

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2017

Obesity, Type 2 Diabetes and Bone in Adults

Adipose, Bone, and Myeloma: Contributions from the Microenvironment

Restrictive Eating Disorders and Skeletal Health in Adolescent Girls and Young Women

Bone Density in the Obese Child: Clinical Considerations and Diagnostic Challenges

The Activity of Adiponectin in Bone

Evolution of the Marrow Adipose Tissue Microenvironment

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page